• Parexel introduced ParexelAI, a proprietary, human-led AI services suite aimed at speeding clinical development workflows across the trial lifecycle.
• The rollout positions Parexel to compete more aggressively on delivery speed, quality consistency, and operating efficiency as sponsors push to shorten timelines.
• Reported results include a 50% cut in site selection timelines, a 30% reduction in clinical study report preparation time, and a 20% reduction in safety literature screening and pharmacovigilance case processing.
• The strategy leans on a mix of in-house tools, partnerships, and the Vitrana acquisition to support a more integrated patient safety and pharmacovigilance offering.
• Partnerships highlighted include Paradigm Health for patient identification and access, Weave Bio for regulatory automation, and Palantir’s AI platform as the backbone for AI-enabled clinical operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parexel International Corporation published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.